Search research articles
Contact Us
Filters
Showing results (421-430 of 643) with videos related to
Page
of 65
Sort By:
JCO Precision Oncology
|
September 11, 2020
Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With <i>BRAF</i> V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study
Vivek Subbiah, Radj Gervais, Gregory Riely, et al.
The Lancet. Oncology
|
March 13, 2019
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Funda Meric-Bernstam, Herbert Hurwitz, Kanwal Pratap Singh Raghav, et al.
The Oncologist
|
August 25, 2018
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer
Reva K Basho, Clinton Yam, Michael Gilcrease, et al.
Journal of Hepatology
|
November 16, 2023
Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma
Timothy P DiPeri, Ming Zhao, Kurt W Evans, et al.
NPJ Precision Oncology
|
April 10, 2026
Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study
Jacopo Venturini, Mehmet A Baysal, Abhijit Chakraborty, et al.
Annals of Surgery
|
January 7, 2011
Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning
Min Yi, Thomas A Buchholz, Funda Meric-Bernstam, et al.
JCO Precision Oncology
|
September 14, 2020
Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients
Jingyu Cao, Jing Hu, Siqin Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 20, 2015
Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors
Rashmi S Goswami, Keyur P Patel, Rajesh R Singh, et al.
Scientific Reports
|
November 23, 2017
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors
Vikas Dembla, Roman Groisberg, Ken Hess, et al.
Breast Cancer Research and Treatment
|
March 7, 2012
Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass
Henry M Kuerer, Sara A Lari, Banu K Arun, et al.
Page
of 65
Search research articles
Search
Showing results (421-430 of 643) with videos related to
Sort By:
Page
of 65
JCO Precision Oncology
|
September 11, 2020
Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With <i>BRAF</i> V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study
Vivek Subbiah, Radj Gervais, Gregory Riely, et al.
The Lancet. Oncology
|
March 13, 2019
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Funda Meric-Bernstam, Herbert Hurwitz, Kanwal Pratap Singh Raghav, et al.
The Oncologist
|
August 25, 2018
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer
Reva K Basho, Clinton Yam, Michael Gilcrease, et al.
Journal of Hepatology
|
November 16, 2023
Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma
Timothy P DiPeri, Ming Zhao, Kurt W Evans, et al.
NPJ Precision Oncology
|
April 10, 2026
Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study
Jacopo Venturini, Mehmet A Baysal, Abhijit Chakraborty, et al.
Annals of Surgery
|
January 7, 2011
Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning
Min Yi, Thomas A Buchholz, Funda Meric-Bernstam, et al.
JCO Precision Oncology
|
September 14, 2020
Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients
Jingyu Cao, Jing Hu, Siqin Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 20, 2015
Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors
Rashmi S Goswami, Keyur P Patel, Rajesh R Singh, et al.
Scientific Reports
|
November 23, 2017
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors
Vikas Dembla, Roman Groisberg, Ken Hess, et al.
Breast Cancer Research and Treatment
|
March 7, 2012
Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass
Henry M Kuerer, Sara A Lari, Banu K Arun, et al.
Page
of 65